Haemonetics Corporation provided revenue guidance for the fiscal year 2025. For the year, the company expects GAAP total reported revenue growth to be between 5% to 8%, and total organic revenue growth to be between 0% to 3%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
83.06 USD | +0.40% |
|
-0.43% | -2.87% |
Jun. 18 | Haemonetics Corporation Launches Limited Market Release of its New VASCADE MVP XL Mid-Bore Venous Closure Device | CI |
Jun. 12 | Haemonetics Shares Rise After Upgrade From Needham | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.87% | 4.22B | |
-6.24% | 180B | |
-6.08% | 98.89B | |
-5.98% | 66.26B | |
-9.35% | 44.61B | |
+8.34% | 44.02B | |
+9.79% | 40.12B | |
+11.88% | 29.19B | |
-8.38% | 23.64B | |
+14.32% | 23.41B |
- Stock Market
- Equities
- HAE Stock
- News Haemonetics Corporation
- Haemonetics Corporation Provides Revenue Guidance for the Fiscal Year 2025